OpGen (OPGN) has risen sharply, recording gains of 44.2% in the past 4 weeks. However, the stock has corrected -10.41% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 42.73% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
The stock has recorded a 20-day Moving Average of 13.5% and the 50-Day Moving Average is 9.43%. OpGen (NASDAQ:OPGN): stock turned positive on Friday. Though the stock opened at $1.91, the bulls momentum made the stock top out at $1.98 level for the day. The stock recorded a low of $1.78 and closed the trading day at $1.98, in the green by 2.59%. The total traded volume for the day was 680,533. The stock had closed at $1.93 in the previous days trading.
The company Insiders own 48.2% of OpGen shares according to the proxy statements. Institutional Investors own 1.31% of OpGen shares. During last six month period, the net percent change held by insiders has seen a change of 34.08%. Also, Rodman & Renshaw initiates coverage on OpGen (NASDAQ:OPGN). In the latest research report, Rodman & Renshaw announces the target price to $2.5 per share. According to the latest information available, the shares are now rated Buy by the analysts at the agency. The rating by the firm was issued on June 29, 2016.
OpGen, Inc. is a United States-based Company that provides optical mapping solutions for life sciences. The Company offers optical mapping services for analysis of microbial, yeast, and fungal genomic architecture. It offers its optical mapping technology for life science, clinical and food microbiology, life science, epidemiology, pharmacology, microbial forensics, manufacturing quality control, and applied research applications. Its map analysis software module includes with the Argus Whole Genome Mapping System, which provides analysis for microbial samples and genomes up to 100Mb.